Article
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy.
The oncologist - 1 Apr 2021
George Suzanne, Jones Robin L, Bauer Sebastian, Kang Yoon-Koo, Schöffski Patrick, Eskens Ferry, Mir Olivier, Cassier Phillipe A, Serrano Cesar, Tap William D, Trent Jonathan, Rutkowski Piotr, Patel Shreyaskumar, Chawla Sant P, Meiri Eval, Gordon Michael, Zhou Teresa, Roche Maria, Heinrich Micahel C, von Mehren Margaret
Abstract excerpt
BACKGROUND: Most gastrointestinal stromal tumors (GIST) driven by KIT or platelet-derived growth factor receptor A (PDGFRA) mutations develop resistance to available tyrosine kinase inhibitor (TKI) treatments. NAVIGATOR is a two-part, single-arm, dose escalation and expansion study designed to evaluate safety and antineoplastic activity of avapritinib, a selective, potent inhibitor of KIT and PDGFRA, in patients...
Topics
Join the communities discussing this publication.